Plexxikon Inc. v. Novartis Pharmaceuticals Corporation

Good Law
United States District Court, Northern District of CaliforniaMay 26, 20204:17-cv-04405California2,733 words

Opinion

Trial Court Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 PLEXXIKON INC., Case No. 17-cv-04405-HSG

Plaintiff, ORDER GRANTING IN PART AND

DENYING IN PART MOTION TO

v. EXCLUDE THE EXPERT TESTIMONY

OF SUSANA ORTIZ-URDA

NOVARTIS PHARMACEUTICALS CORPORATION, Re: Dkt. No. 204 11 Defendant. 12 Pending before the Court is Defendant Novartis Pharmaceuticals Corporation’s motion to exclude the testimony of Plaintiff Plexxikon Inc.’s expert Susana Ortiz-Urda. Dkt. No. 204. The Court heard argument on this motion on November 1, 2019. See Dkt. No. 341. As detailed below, the Court GRANTS IN PART and DENIES IN PART the motion. I. BACKGROUND Defendant challenges the testimony of Plaintiff’s clinical expert, Dr. Susana Ortiz-Urda, as speculative and not based on any reliable methodology. Dkt. No. 204. In her expert report, Dr. Ortiz-Urda offers opinions about the treatment of melanoma, its evolution, and how physicians would respond in the hypothetical scenario in…

Sign in to read the full opinion

Create a free account to read the complete opinion text, citation history, and good-law status for this case.